drugset / Trial / NCT00422422

Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.

NCT00422422

Phase 2 Completed 100 enrolled UCB Pharma
NaSingle-groupOpen-labelTreatment

Summary

Initial study in children with epilepsy to evaluate the pharmacokinetics, safety, tolerability and preliminary efficacy of adjunctive treatment with brivaracetam, and to develop dosing adaptations for future studies.

Timeline

Start
2011-07
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivaracetam Small molecule 1.6 mg/kg Oral
Subject Brivaracetam Small molecule 2 mg/kg Oral

Indications